Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93465Research ArticlePraktika lecheniya bolevykh sindromovMalakhovskayaL. N-1502201113210711028122021Copyright © 2011, Consilium Medicum2011[Каратеев А.Е., Барскова В.Г. Критерии выбора нестероидного противовоспалительного препарата. Справ. практ. врача. 2007; 5 (5): 13–7.][Насонов Е.Л. Кардиоваскулярные осложнения ингибиторов ЦОГ-2 – вопросов больше, чем ответов. Рус. мед. журн. 2005; 13 (7): 383–91.][Насонов Е.Л., Каратеев А.Е. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Рус. мед. журн. 2006; 14 (25): 1769–77.][Boutsen Y, Esselinckx W. Novel nonsteroidal anti - inflammatory drugs. Acta Gastroenterol Belg 1999; 62 (4): 421–4.][Du Bois R.N., Abramson S.B., Crofford L et al. Cyclooxygenase in biology and medicine. FASEB J 1998; 12: 1063–73.][Feldman M, Mc Mahon A.T. Do cyclooxigenase - 2 inhibitors provide benefits similar to those of traditional nonsteroidal anti - inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134–43.][Goldring M.B., Berenbaum F. The regulation of chondrocyte function by proinflamatory mediators: prostaglandins and nitric oxide. Clin Orthop 2004.][Goldring M.B., Otero M, Tsuchimochi K et al. Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. Ann rheum Dis 2008; 67 (Suppl III): 75–82.][Hawkey C, Kahan A, Steinbruck K et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37: 937–45.][Peloso P.M., Scheiman J.M. The economic implications of cyclooxygenase2 - specific inhibitors. Am J Med 2001; 110: 50S–54S.][Rainsford K.D. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal antiinflammatory drugs (NSAIDs). Am J Med 1999; 107 (6A): 27S–35S.][Silver D.S. The Use of COX - I -Sparing Agents in the Federal Health System. P&T 2004; 29 (7): 454–8.][Singh G, Triadafilopoulos G. Meloxicam has a low risk of serious gastrointestinal complications: Pooled analysis of 27,039 patients (Abstract SAT0085). European League Against Rheumatism (EULAR) 2001.][Wolfe M, Lichtenstein D.R., Sinhg G. Gastrointestinal toxicity on nonsteroidal anti - inflammatory drugs. N Engl J Med 1999; 24: 1888–9.][Zeidler H, Kaltwasser J.P., Leonard J.P. et al. Prescription and Tolerability of Meloxicam in Day - to - Day Practice: Postmarketing Observational Cohort Study of 13,307 Patients in Germany. J Clin Rheumatol 2002; 8 (6): 305–15.]